{"id":1289,"date":"2015-04-28T10:43:58","date_gmt":"2015-04-28T08:43:58","guid":{"rendered":"http:\/\/semmelweis.hu\/patologia1\/?page_id=1289"},"modified":"2025-08-01T12:25:05","modified_gmt":"2025-08-01T10:25:05","slug":"phd-kepzes","status":"publish","type":"page","link":"https:\/\/semmelweis.hu\/patologia1\/phd-kepzes\/","title":{"rendered":"PhD k\u00e9pz\u00e9s"},"content":{"rendered":"<p style=\"text-align: center\"><strong>A doktori (PhD) k\u00e9pz\u00e9sben r\u00e9szt vev\u0151 hallgat\u00f3ink a <a href=\"https:\/\/semmelweis.hu\/phd\/doktori-iskolak\/patologiai-tudomanyok-multidiszciplinaris-orvostudomanyok\/\">Patol\u00f3giai Tudom\u00e1nyok Doktori Iskola<\/a> Onkol\u00f3gia programj\u00e1nak keretein bel\u00fcl folytatj\u00e1k tanulm\u00e1nyaikat.<\/strong><\/p>\n<p>&nbsp;<\/p>\n<p style=\"text-align: justify\">A 2020 \u0151sz\u00e9n meg\u00fajult k\u00e9pz\u00e9si tervvel indul\u00f3 Onkol\u00f3gia program c\u00e9lja, hogy a hallgat\u00f3k az onkogenezis molekul\u00e1ris h\u00e1tter\u00e9nek meg\u00e9rt\u00e9s\u00e9n t\u00fal ismereteket szerezzenek a klinikai \u00e9s transzl\u00e1ci\u00f3s onkol\u00f3gia ter\u00e9n is. Az elm\u00e9leti ismereteken t\u00fal a korszer\u0171 daganatkutat\u00e1shoz sz\u00fcks\u00e9ges gyakorlati k\u00e9pess\u00e9gek megszerz\u00e9s\u00e9re is hangs\u00falyt fektet a k\u00e9pz\u00e9si program. A gyakorlati kurzusok sor\u00e1n az adatelemz\u00e9s, a molekul\u00e1ris genetikai m\u00f3dszerek, k\u00fcl\u00f6nb\u00f6z\u0151 in vitro \u00e9s in vivo modellrendszerek bemutat\u00e1sa \u00e9s alapszint\u0171 gyakorlati megismer\u00e9s\u00e9re is lehet\u0151s\u00e9g ny\u00edlik. A k\u00e9pz\u00e9si terv kiemelt c\u00e9lja a szem\u00e9lyre szabott diagnosztika \u00e9s ter\u00e1pia koncepci\u00f3j\u00e1hoz kapcsol\u00f3d\u00f3 ismeretek szint\u00e9zise az alapkutat\u00e1s m\u00f3dszereit\u0151l eg\u00e9szen a legkorszer\u0171bb kezel\u00e9si modalit\u00e1sokig.<\/p>\n<p>&nbsp;<\/p>\n<p><strong>A k\u00e9pz\u00e9s els\u0151 k\u00e9t \u00e9v\u00e9ben az al\u00e1bbi elm\u00e9leti \u00e9s gyakorlati kurzusok ker\u00fclnek meghirdet\u00e9sre az Onkol\u00f3gia Program hallgat\u00f3inak r\u00e9sz\u00e9re: <br \/>\n<\/strong><\/p>\n<p><span style=\"text-decoration: underline\">Elm\u00e9leti kurzusok:<\/span><\/p>\n<ul>\n<li><strong>Klinikai Onkol\u00f3gia<\/strong> (Dr. Sebesty\u00e9n Anna), (k\u00f6telez\u0151)<\/li>\n<li><strong>Molekul\u00e1ris Onkol\u00f3gia I. <\/strong>(Dr. B\u00f6d\u00f6r Csaba), (k\u00f6telez\u0151)<\/li>\n<li><strong>Transzl\u00e1ci\u00f3s Onkol\u00f3gia <\/strong>(Kren\u00e1cs Tibor), (k\u00f6telez\u0151)<\/li>\n<li><strong>Digt\u00e1lis Patol\u00f3gia<\/strong> (Dr. F\u00f3nyad L\u00e1szl\u00f3, Dr. Micsik Tam\u00e1s), (k\u00f6telez\u0151en v\u00e1laszthat\u00f3)<\/li>\n<li><strong>Bioinformatika<\/strong> (Dr. Gy\u0151rffy Bal\u00e1zs), (k\u00f6telez\u0151en v\u00e1laszthat\u00f3)<\/li>\n<li><strong>Tumorprogresszi\u00f3 \u00e9s el\u0151rejelz\u00e9se<\/strong> (Dr. T\u00edm\u00e1r J\u00f3zsef), (k\u00f6telez\u0151en v\u00e1laszthat\u00f3)<\/li>\n<li><strong>A pancreasr\u00e1k patol\u00f3giai alapjai \u00e9s ter\u00e1pi\u00e1s vonzatai<\/strong> (Dr. Zalatnai Attila), (v\u00e1laszthat\u00f3)<em><br \/>\n<\/em><em>Nem orvos v\u00e9gzetts\u00e9g\u0171 hallgat\u00f3k sz\u00e1m\u00e1ra:<\/em><\/li>\n<li><strong>Patol\u00f3giai alapismeretek biol\u00f3gusoknak<\/strong> (Dr. Fintha Attila, Dr. Tim\u00e1r Botond), (k\u00f6telez\u0151)<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><span style=\"text-decoration: underline\">Gyakorlati kurzusok:<\/span><\/p>\n<ul style=\"list-style-type: square\">\n<li><strong>In vitro \u00e9s in vivo modellek a daganatkutat\u00e1sban <\/strong>(Sebesty\u00e9n Anna, Dezs\u0151 Kata), (k\u00f6telez\u0151en v\u00e1laszthat\u00f3)<\/li>\n<li><strong>Adatelemz\u00e9s \u00e9s programoz\u00e1s orvosbiol\u00f3gusoknak I.<\/strong> (Sebesty\u00e9n Endre, Cserz\u0151 Mikl\u00f3s), (k\u00f6telez\u0151en v\u00e1laszthat\u00f3)<\/li>\n<li><strong>Az \u00e1raml\u00e1si citometria alapjai \u00e9s felhaszn\u00e1l\u00e1sa <\/strong>(Barna G\u00e1bor, Szal\u00f3ki G\u00e1bor), (k\u00f6telez\u0151en v\u00e1laszthat\u00f3)<\/li>\n<li><strong>Molekul\u00e1ris Onkol\u00f3gia II. <\/strong>(B\u00f6d\u00f6r Csaba, Alp\u00e1r Don\u00e1t), (k\u00f6telez\u0151en v\u00e1laszthat\u00f3)<br \/>\n<strong>Adatelemz\u00e9s \u00e9s programoz\u00e1s orvosbiol\u00f3gusoknak II.<\/strong> (Cserz\u0151 Mikl\u00f3s, Sebesty\u00e9n Endre), (v\u00e1laszthat\u00f3)<\/li>\n<li><strong>Alkalmazott bioinformatika az onkol\u00f3gi\u00e1ban<\/strong> (Dr. Gy\u0151rffy Bal\u00e1zs), (k\u00f6telez\u0151en v\u00e1laszthat\u00f3)<\/li>\n<li><strong>El\u0151ad\u00e1stechnika <\/strong>(Szal\u00f3ki G\u00e1bor), (v\u00e1laszthat\u00f3)<\/li>\n<li><strong>Journal Club <\/strong>(B\u00f6d\u00f6r Csaba), (v\u00e1laszthat\u00f3)<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><u>Egy\u00e9b javasolt kurzusok:<\/u><\/p>\n<ul style=\"list-style-type: square\">\n<li><strong>Biostatisztika kurzus\u00a0(008-KVA-1) <\/strong>(Dr. Dinya Elek)<\/li>\n<li><strong>Irodalomkutat\u00e1si m\u00f3dszerek (DI0013KV_1M) <\/strong>(K\u00f6zponti k\u00f6nyvt\u00e1r szervez\u00e9s\u00e9ben)<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><strong>Int\u00e9zet\u00fcnk oktat\u00f3i \u00e1ltal meghirdetett PhD t\u00e9m\u00e1k:<\/strong><\/p>\n<table style=\"width: 89.9185%\" width=\"1037\">\n<tbody>\n<tr>\n<td style=\"width: 19.5466%\" width=\"198\">Alp\u00e1r Don\u00e1t<\/td>\n<td style=\"width: 96.0186%\" width=\"839\">Malignus hemopoetikus betegs\u00e9gek heterogenit\u00e1sa \u00e9s evol\u00faci\u00f3ja<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 19.5466%\">Baghy Korn\u00e9lia<\/td>\n<td style=\"width: 96.0186%\">A SPOCK1 proteoglik\u00e1n szerepe a daganatok kialakul\u00e1s\u00e1ban \u00e9s progresszi\u00f3j\u00e1ban<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 19.5466%\">Barna G\u00e1bor<\/td>\n<td style=\"width: 96.0186%\">A B-sejtes lymphom\u00e1k ter\u00e1pia rezisztens sejtjeiben megjelen\u0151 jel\u00e1tviteli \u00fatjainak kutat\u00e1sa \u00e1raml\u00e1si citometriai \u00e9s molekul\u00e1ris m\u00f3dszerekkel<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 19.5466%\">B\u00f6d\u00f6r Csaba<\/td>\n<td style=\"width: 96.0186%\">Kr\u00f3nikus myeloproliferat\u00edv neopl\u00e1zi\u00e1k klinikopatol\u00f3giai vizsg\u00e1lata<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 19.5466%\">B\u00f6d\u00f6r Csaba<\/td>\n<td style=\"width: 96.0186%\">Genetikai markerek kr\u00f3nikus lymphoid leukaemi\u00e1ban<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 19.5466%\">B\u00f6d\u00f6r Csaba<\/td>\n<td style=\"width: 96.0186%\">Lymphom\u00e1k \u00e9s leukaemi\u00e1k genetikai \u00e9s epigenetikai h\u00e1tter\u00e9nek vizsg\u00e1lata<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 19.5466%\">Dezs\u0151 Katalin<\/td>\n<td style=\"width: 96.0186%\">A szomatikus \u0151ssejtek szerepe a m\u00e1jcirr\u00f3zis kialakul\u00e1s\u00e1ban<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 19.5466%\">Kiss Rich\u00e1rd<\/td>\n<td style=\"width: 96.0186%\">Gyermekkori extrakrani\u00e1lis szolid tumorok genetikai \u00e9s epigenetikai h\u00e1tter\u00e9nek felt\u00e9rk\u00e9pez\u00e9se<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 19.5466%\">Kov\u00e1cs \u00c1rp\u00e1d Ferenc<\/td>\n<td style=\"width: 96.0186%\">Egy-sejt multiomikai vizsg\u00e1latok T-sejt asszoci\u00e1lt k\u00f3rk\u00e9pekben<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 19.5466%\">Kovalszky Ilona<\/td>\n<td style=\"width: 96.0186%\">Extracellul\u00e1ris m\u00e1trix molekul\u00e1k szerepe a m\u00e1jsz\u00f6vet biol\u00f3giai viselked\u00e9s\u00e9nek szab\u00e1lyoz\u00e1s\u00e1ban.<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 19.5466%\">Kren\u00e1cs Tibor<\/td>\n<td style=\"width: 96.0186%\">A myelofibr\u00f3zis progresszi\u00f3j\u00e1nak molekul\u00e1ris morfol\u00f3giai monitoroz\u00e1sa \u00e9s az immunfenot\u00edpus genetikai \u00f6sszef\u00fcgg\u00e9sei<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 19.5466%\" width=\"198\">Kren\u00e1cs Tibor<\/td>\n<td style=\"width: 96.0186%\" width=\"839\">Prognosztikai \u00e9s predikt\u00edv faktorok vizsg\u00e1lata in situ feh\u00e9rje, ill. g\u00e9n szinten: immunhisztok\u00e9miai \u00e9s fluoreszcens in situ hibridiz\u00e1ci\u00f3 (FISH) jeleinek mennyis\u00e9gi \u00e9s min\u0151s\u00e9gi elemz\u00e9se automatiz\u00e1lt digit\u00e1lis k\u00e9panal\u00edzissel malignus daganatokban<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 19.5466%\">Kren\u00e1cs Tibor<\/td>\n<td style=\"width: 96.0186%\">Prognosztikus biomarkerek kutat\u00e1sa tripla negat\u00edv eml\u0151carcinom\u00e1ban (TNBC)<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 19.5466%\">Krencz Ildik\u00f3<\/td>\n<td style=\"width: 96.0186%\">Metabolikus plaszticit\u00e1s \u00e9s heterogenit\u00e1s vizsg\u00e1lata t\u00fcd\u0151daganatokban<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 19.5466%\">Matolcsy Andr\u00e1s<\/td>\n<td style=\"width: 96.0186%\">A lymphom\u00e1k kialakul\u00e1s\u00e1ban \u00e9s progresszi\u00f3j\u00e1ban szerepet j\u00e1tsz\u00f3 molekul\u00e1ris genetikai t\u00e9nyez\u0151k vizsg\u00e1lata<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 19.5466%\">Micsik Tam\u00e1s<\/td>\n<td style=\"width: 96.0186%\">Tumorok \u00e9s betegs\u00e9gek szubt\u00edpusainak komplex klinikopatol\u00f3giai \u00e9s digit\u00e1lis patol\u00f3giai megk\u00f6zel\u00edt\u00e9se<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 19.5466%\">Nagy P\u00e9ter<\/td>\n<td style=\"width: 96.0186%\">A m\u00e1j \u0151ssejtek szerepe a m\u00e1j patol\u00f3gi\u00e1s folyamataiban \u00e9s a carcinogenezisben<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 19.5466%\">P\u00e1pay Judit<\/td>\n<td style=\"width: 96.0186%\">T\u00fcd\u0151r\u00e1kok molekul\u00e1ris patol\u00f3gi\u00e1ja<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 19.5466%\">Reiniger Lilla<\/td>\n<td style=\"width: 96.0186%\">Primer \u00e9s szekunder k\u00f6zponti idegrendszeri daganatok genomikai \u00e9s epigenomikai vizsg\u00e1lata<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 19.5466%\">Reiniger Lilla<\/td>\n<td style=\"width: 96.0186%\">A chronicus lymphocyt\u00e1s leukaemia genomikai \u00e9s epigenomikai vizsg\u00e1lata<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 19.5466%\">S\u00e1pi Zolt\u00e1n<\/td>\n<td style=\"width: 96.0186%\">Az INI1 szupresszor g\u00e9n vizsg\u00e1lata epitheloid sarcom\u00e1kban<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 19.5466%\">S\u00e1pi Zolt\u00e1n<\/td>\n<td style=\"width: 96.0186%\">Karcinogenesis modellez\u00e9se synovialis sarcom\u00e1ban<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 19.5466%\">Sebesty\u00e9n Anna<\/td>\n<td style=\"width: 96.0186%\" width=\"839\">Pro-apoptotikus szab\u00e1lyoz\u00f3k hat\u00e1s\u00e1nak helyre\u00e1ll\u00edt\u00e1sa, kemoter\u00e1pi\u00e1s szerek hat\u00e1s\u00e1nak fokoz\u00e1sa k\u00fcl\u00f6nb\u00f6z\u0151 jel\u00e1tviteli mechanizmusokon kereszt\u00fcl<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 19.5466%\">Sebesty\u00e9n Anna<\/td>\n<td style=\"width: 96.0186%\" width=\"839\">Daganatsejtek \u00e9s a daganatsz\u00f6vet metabolikus v\u00e1ltoz\u00e1sai, heterogenit\u00e1sa \u00e9s annak modellez\u00e9se<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 19.5466%\">Sz\u00e1ll\u00e1si \u00c1rp\u00e1d<\/td>\n<td style=\"width: 96.0186%\">Tumor-associated Carbohydrate Antigen (TACA) expresszi\u00f3 vizsg\u00e1lata szolid tumorokban<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 19.5466%\">Sz\u00e1ll\u00e1si \u00c1rp\u00e1d<\/td>\n<td style=\"width: 96.0186%\">TRP csatorna expresszi\u00f3 vizsg\u00e1lata malignus tumorokban: diagn\u00f3zis, progn\u00f3zis, ter\u00e1pia<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 19.5466%\">T\u00edm\u00e1r Botond<\/td>\n<td style=\"width: 96.0186%\">Myeloid neopl\u00e1zi\u00e1k komprehenz\u00edv genetikai \u00e9s klinikopatol\u00f3giai jellemz\u00e9se<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr \/>\n<table style=\"width: 90.16%\" width=\"487\">\n<tbody>\n<tr>\n<td style=\"width: 53.4266%\" width=\"423\">dr. Barna G\u00e1bor, dr. Szal\u00f3ki G\u00e1bor, dr. M\u00e1rk \u00c1gnes, dr. Tolnai-Kriston Csilla<\/td>\n<td style=\"width: 188.614%\" width=\"64\">Az \u00e1raml\u00e1s citomeria alapjai \u00e9s felhaszn\u00e1l\u00e1sa \u2002<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 53.4266%\">Dr. Fintha Attila, Dr. T\u00edm\u00e1r Botond<\/td>\n<td style=\"width: 188.614%\">Patol\u00f3giai alapismeretek biol\u00f3gusoknak\/Basic pathology for biologists<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 53.4266%\">Dr. Kren\u00e1cs Tibor<\/td>\n<td style=\"width: 188.614%\">Tumormarkerek molekul\u00e1ris &#8211; morfol\u00f3giai kuat\u00e1sa\/Molecular morphology eresearch of tumor markers : relevance for diagnostics and therapy<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr \/>\n<p>&nbsp;<\/p>\n<p>Patol\u00f3giai \u00e9s Onkol\u00f3giai tagozatvezet\u0151:<strong><br \/>\nDr. Matolcsy Andr\u00e1s<\/strong><br \/>\nPatol\u00f3giai\u00a0 \u00e9s K\u00eds\u00e9rleti R\u00e1kkutat\u00f3 Int\u00e9zet<br \/>\n<strong>Telefon:<\/strong>\u00a0+36 1 266-1637<\/p>\n<p>Molekul\u00e1ris \u00e9s experiment\u00e1lis onkol\u00f3giai programvezet\u0151: <br \/>\n<strong>Dr. B\u00f6d\u00f6r Csaba<\/strong><br \/>\nbodor.csaba1@semmelweis.hu<\/p>\n<p>\u00dcgyint\u00e9z\u0151:<br \/>\n<strong>Laczik Cec\u00edlia<\/strong><br \/>\nPatol\u00f3giai\u00a0 \u00e9s K\u00eds\u00e9rleti R\u00e1kkutat\u00f3 Int\u00e9zet<br \/>\n<strong>Telefon:<\/strong>\u00a0+36 1 266-1637 \/ 54437<\/p>\n<p>&nbsp;<\/p>\n<p>Int\u00e9zet\u00fcnkben dolgoz\u00f3 <a href=\"https:\/\/semmelweis.hu\/patologia1\/bemutatkozas\/munkatarsak\/phd-hallgatok\/\"><strong>PhD hallgat\u00f3k<\/strong><\/a> list\u00e1ja.<\/p>\n<p>A doktori k\u00e9pz\u00e9sr\u0151l b\u0151vebb inform\u00e1ci\u00f3hoz a <a href=\"https:\/\/semmelweis.hu\/phd\/\"><strong>Doktori Iskola honlapj\u00e1n<\/strong><\/a> lehet jutni.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A doktori (PhD) k\u00e9pz\u00e9sben r\u00e9szt vev\u0151 hallgat\u00f3ink a <a href=\"https:\/\/semmelweis.hu\/phd\/doktori-iskolak\/patologiai-tudomanyok-multidiszciplinaris-orvostudomanyok\/\">Patol\u00f3giai Tudom\u00e1nyok Doktori Iskola<\/a> Onkol\u00f3gia programj\u00e1nak keretein bel\u00fcl folytatj\u00e1k tanulm\u00e1nyaikat. &nbsp; A 2020 \u0151sz\u00e9n meg\u00fajult k\u00e9pz\u00e9si tervvel indul\u00f3 Onkol\u00f3gia program c\u00e9lja, hogy a hallgat\u00f3k az onkogenezis molekul\u00e1ris h\u00e1tter\u00e9nek meg\u00e9rt\u00e9s\u00e9n t\u00fal ismereteket szerezzenek a klinikai \u00e9s transzl\u00e1ci\u00f3s onkol\u00f3gia ter\u00e9n is. Az elm\u00e9leti ismereteken t\u00fal a korszer\u0171 daganatkutat\u00e1shoz sz\u00fcks\u00e9ges gyakorlati k\u00e9pess\u00e9gek megszerz\u00e9s\u00e9re is &hellip;<\/p>\n","protected":false},"author":54,"featured_media":0,"parent":0,"menu_order":5,"comment_status":"open","ping_status":"open","template":"","meta":{"_acf_changed":false,"footnotes":""},"categories":[],"tags":[],"class_list":["post-1289","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/semmelweis.hu\/patologia1\/wp-json\/wp\/v2\/pages\/1289","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/semmelweis.hu\/patologia1\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/semmelweis.hu\/patologia1\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/patologia1\/wp-json\/wp\/v2\/users\/54"}],"replies":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/patologia1\/wp-json\/wp\/v2\/comments?post=1289"}],"version-history":[{"count":11,"href":"https:\/\/semmelweis.hu\/patologia1\/wp-json\/wp\/v2\/pages\/1289\/revisions"}],"predecessor-version":[{"id":8728,"href":"https:\/\/semmelweis.hu\/patologia1\/wp-json\/wp\/v2\/pages\/1289\/revisions\/8728"}],"wp:attachment":[{"href":"https:\/\/semmelweis.hu\/patologia1\/wp-json\/wp\/v2\/media?parent=1289"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/semmelweis.hu\/patologia1\/wp-json\/wp\/v2\/categories?post=1289"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/semmelweis.hu\/patologia1\/wp-json\/wp\/v2\/tags?post=1289"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}